231 related articles for article (PubMed ID: 12084321)
1. Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs.
Kyprianou N; Jacobs SC
Curr Urol Rep; 2000 Aug; 1(2):89-96. PubMed ID: 12084321
[TBL] [Abstract][Full Text] [Related]
2. Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Kyprianou N; Chon J; Benning CM
Prostate Suppl; 2000; 9():42-6. PubMed ID: 11056502
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
4. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Kyprianou N; Benning CM
Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
[TBL] [Abstract][Full Text] [Related]
5. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Kyprianou N
J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
[TBL] [Abstract][Full Text] [Related]
6. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
7. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
Benning CM; Kyprianou N
Cancer Res; 2002 Jan; 62(2):597-602. PubMed ID: 11809715
[TBL] [Abstract][Full Text] [Related]
8. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Keledjian K; Kyprianou N
J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
[TBL] [Abstract][Full Text] [Related]
9. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
Cuellar DC; Rhee J; Kyprianou N
Anticancer Res; 2002; 22(3):1673-9. PubMed ID: 12168853
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
11. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia.
Kyprianou N; Litvak JP; Borkowski A; Alexander R; Jacobs SC
J Urol; 1998 Jun; 159(6):1810-5. PubMed ID: 9598465
[TBL] [Abstract][Full Text] [Related]
12. Comparison of relaxation responses of cavernous and trigonal smooth muscles from rabbits by alpha1-adrenoceptor antagonists; prazosin, terazosin, doxazosin, and tamsulosin.
Seo KK; Lee MY; Lim SW; Kim SC
J Korean Med Sci; 1999 Feb; 14(1):69-74. PubMed ID: 10102527
[TBL] [Abstract][Full Text] [Related]
13. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
Keledjian K; Borkowski A; Kim G; Isaacs JT; Jacobs SC; Kyprianou N
Prostate; 2001 Jul; 48(2):71-8. PubMed ID: 11433417
[TBL] [Abstract][Full Text] [Related]
14. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
Glassman DT; Chon JK; Borkowski A; Jacobs SC; Kyprianou N
Prostate; 2001 Jan; 46(1):45-51. PubMed ID: 11170131
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA
J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424
[TBL] [Abstract][Full Text] [Related]
16. Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Forbes A; Anoopkumar-Dukie S; Chess-Williams R; McDermott C
Prostate; 2016 Jun; 76(8):757-66. PubMed ID: 26880388
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia.
Erdoğru T; Ciftcioglu MA; Emreoglu I; Usta MF; Koksal T; Ozbilim G; Gulkesen KH; Baykara M
Urol Int; 2002; 69(4):287-92. PubMed ID: 12444285
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
Thomas D; Wimmer AB; Wu K; Hammerling BC; Ficker EK; Kuryshev YA; Kiehn J; Katus HA; Schoels W; Karle CA
Naunyn Schmiedebergs Arch Pharmacol; 2004 May; 369(5):462-72. PubMed ID: 15098086
[TBL] [Abstract][Full Text] [Related]
19. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
Chapple CR
Eur Urol; 1996; 29(2):129-44. PubMed ID: 8647139
[TBL] [Abstract][Full Text] [Related]
20. Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
Doggrell SA
Expert Opin Pharmacother; 2004 May; 5(5):1209-11. PubMed ID: 15155119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]